CERo Therapeutics has announced that Colorado Blood Cancer Institute’s (CBCI) Sarah Cannon Research Institute (SCRI), US, will be the main site for its Phase I study evaluating CER-1236 to treat acute ...

Dual Trials Accelerate VELDONA® Toward Rare Disease Market EntryBridging Strategy Aims to Fast-Track U.S. Regulatory Approvals SAN DIEGO, CALIFORNIA / ACCESS Newswire / April 14, 2025 / Ainos, Inc. (N ...

The Trump administration's aggressive global tariff regime against imported goods from some of its closest allies has drawn strong reactions across the board.

Interim Results from FDA-Funded Study Reinforces HyBryte's Rapid Response and Strong Safety Profile PRINCETON, N.J., April 14, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix ...

The study's primary endpoint is overall survival (OS) and the secondary endpoints include progression-free survival (PFS), objective response rate (ORR) and disease control rate (DCR). The ...

The study results show that hOMSC200 is safe and did not elicit any immune response ... The primary end point was safety, including treatment-related adverse events and immunological rejection ...

Discover a study where researchers identified a marked decline in monocyte function and maturation during the ...

Another important area is protective immunity and memory T cell response. While antibody production following vaccination typically lasts about six months, what's more crucial is whether the vaccine ...

Antibodies are best known for their ability to latch onto and neutralize bacteria, viruses and other pathogens. But these immune proteins can do more than that: They also activate other components of ...